SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Simon Eckermann, Brita Pekarsky, Can the Real Opportunity Cost Stand Up: Displaced Services, the Straw Man Outside the Room, PharmacoEconomics, 2014, 32, 4, 319

    CrossRef

  2. 2
    Haitham W. Tuffaha, Claire M. Rickard, Joan Webster, Nicole Marsh, Louisa Gordon, Marianne Wallis, Paul A. Scuffham, Cost-Effectiveness Analysis of Clinically Indicated Versus Routine Replacement of Peripheral Intravenous Catheters, Applied Health Economics and Health Policy, 2014, 12, 1, 51

    CrossRef

  3. 3
    Heejung Bang, Hongwei Zhao, Cost-Effectiveness Analysis: A Proposal of New Reporting Standards in Statistical Analysis, Journal of Biopharmaceutical Statistics, 2014, 24, 2, 443

    CrossRef

  4. 4
    Lotte MG Steuten, Scott D Ramsey, Improving early cycle economic evaluation of diagnostic technologies, Expert Review of Pharmacoeconomics & Outcomes Research, 2014, 14, 4, 491

    CrossRef

  5. 5
    Zafar Zafari, Kristian Thorlund, J. Mark FitzGerald, Carlo A. Marra, Mohsen Sadatsafavi, Network vs. Pairwise Meta-Analyses: A Case Study of the Impact of an Evidence-Synthesis Paradigm on Value of Information Outcomes, PharmacoEconomics, 2014,

    CrossRef

  6. 6
    Lusine Abrahamyan, Andrew R. Willan, Joseph Beyene, Marjorie Mclimont, Victor Blanchette, Brian M. Feldman, Using Value-of-Information Methods when the Disease Is Rare and the Treatment Is Expensive—The Example of Hemophilia A, Journal of General Internal Medicine, 2014,

    CrossRef

  7. 7
    Haitham W. Tuffaha, Louisa G. Gordon, Paul A. Scuffham, Value of information analysis in healthcare: a review of principles and applications, Journal of Medical Economics, 2014, 17, 6, 377

    CrossRef

  8. 8
    Maggie Hong Chen, Andrew R. Willan, Value of information methods for assessing a new diagnostic test, Statistics in Medicine, 2014, 33, 11
  9. 9
    Lotte Steuten, Gijs Wetering, Karin Groothuis-Oudshoorn, Valesca Retèl, A Systematic and Critical Review of the Evolving Methods and Applications of Value of Information in Academia and Practice, PharmacoEconomics, 2013, 31, 1, 25

    CrossRef

  10. 10
    Seamus Kent, Andrew Briggs, Simon Eckermann, Colin Berry, ARE VALUE OF INFORMATION METHODS READY FOR PRIME TIME? AN APPLICATION TO ALTERNATIVE TREATMENT STRATEGIES FOR NSTEMI PATIENTS, International Journal of Technology Assessment in Health Care, 2013, 29, 04, 435

    CrossRef

  11. 11
    Helen Dakin, Sarah Wordsworth, COST-MINIMISATION ANALYSIS VERSUS COST-EFFECTIVENESS ANALYSIS, REVISITED, Health Economics, 2013, 22, 1
  12. 12
    Rahber Thariani, Norah Lynn Henry, Scott D Ramsey, David K Blough, Bill Barlow, Julie R Gralow, David L Veenstra, Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis, Journal of Comparative Effectiveness Research, 2013, 2, 3, 325

    CrossRef

  13. 13
    Simon Eckermann, Andrew R. Willan, Optimal Global Value of Information Trials: Better Aligning Manufacturer and Decision Maker Interests and Enabling Feasible Risk Sharing, PharmacoEconomics, 2013, 31, 5, 393

    CrossRef

  14. 14
    Mohsen Sadatsafavi, Carlo Marra, Stirling Bryan, TWO-LEVEL RESAMPLING AS A NOVEL METHOD FOR THE CALCULATION OF THE EXPECTED VALUE OF SAMPLE INFORMATION IN ECONOMIC TRIALS, Health Economics, 2013, 22, 7
  15. 15
    Valesca P. Retèl, Janneke P.C. Grutters, Wim H. van Harten, Manuela A. Joore, Value of Research and Value of Development in Early Assessments of New Medical Technologies, Value in Health, 2013, 16, 5, 720

    CrossRef

  16. 16
    Andrew R. Willan, Simon Eckermann, ACCOUNTING FOR BETWEEN-STUDY VARIATION IN INCREMENTAL NET BENEFIT IN VALUE OF INFORMATION METHODOLOGY, Health Economics, 2012, 21, 10
  17. 17
    Judith van Loon, Janneke Grutters, Fergus Macbeth, Evaluation of novel radiotherapy technologies: what evidence is needed to assess their clinical and cost effectiveness, and how should we get it?, The Lancet Oncology, 2012, 13, 4, e169

    CrossRef

  18. 18
    Andrew R. Willan, Simon Eckermann, Value of Information and Pricing New Healthcare Interventions, PharmacoEconomics, 2012, 30, 6, 447

    CrossRef

  19. 19
    Andrew R. Willan, Ron Goeree, Kathy Boutis, Value of information methods for planning and analyzing clinical studies optimize decision making and research planning, Journal of Clinical Epidemiology, 2012, 65, 8, 870

    CrossRef

  20. 20
    O. Gajic-Veljanoski, A. M. Bayoumi, G. Tomlinson, K. Khan, A. M. Cheung, Vitamin K supplementation for the primary prevention of osteoporotic fractures: is it cost-effective and is future research warranted?, Osteoporosis International, 2012, 23, 11, 2681

    CrossRef

  21. 21
    R.M. Sladek, T. Jones, P.A. Phillips, M. Luszcz, D. Rowett, S. Eckermann, R.J. Woodman, P. Frith, Health, economic, psychological and social impact of educating carers of patients with advanced pulmonary disease (protocol), Contemporary Clinical Trials, 2011, 32, 5, 717

    CrossRef

  22. 22
    Simon Eckermann, Andrew R. Willan, Presenting Evidence and Summary Measures to Best Inform Societal Decisions When Comparing Multiple Strategies, PharmacoEconomics, 2011, 1

    CrossRef

  23. 23
    Andrew R. Willan, Sample Size Determination for Cost-Effectiveness Trials, PharmacoEconomics, 2011, 29, 11, 933

    CrossRef

  24. 24
    Adam G. Elshaug, Taryn Bessen, John R. Moss, Janet E. Hiller, Addressing “Waste” in Diagnostic Imaging: Some Implications of Comparative Effectiveness Research, Journal of the American College of Radiology, 2010, 7, 8, 603

    CrossRef

  25. 25
    Claire McKenna, Zaid Chalabi, David Epstein, Karl Claxton, Budgetary policies and available actions: A generalisation of decision rules for allocation and research decisions, Journal of Health Economics, 2010, 29, 1, 170

    CrossRef

  26. 26
    Adrian Towse, Louis P. Garrison, Canʼt Get No Satisfaction? Will Pay for Performance Help?, PharmacoEconomics, 2010, 28, 2, 93

    CrossRef

  27. 27
    Peter S. Hall, Christopher McCabe, Julia M. Brown, David A. Cameron, Health economics in drug development: Efficient research to inform healthcare funding decisions, European Journal of Cancer, 2010, 46, 15, 2674

    CrossRef

  28. 28
    Martin Hoyle, Historical Lifetimes of Drugs in England: Application to Value of Information and Cost-Effectiveness Analyses, Value in Health, 2010, 13, 8
  29. 29
    Andrew R. Willan, Simon Eckermann, Optimal clinical trial design using value of information methods with imperfect implementation, Health Economics, 2010, 19, 5
  30. 30
    Janneke P.C. Grutters, Madelon Pijls-Johannesma, Dirk De Ruysscher, Andrea Peeters, Stefan Reimoser, Johan L. Severens, Philippe Lambin, Manuela A. Joore, The cost-effectiveness of particle therapy in non-small cell lung cancer: Exploring decision uncertainty and areas for future research, Cancer Treatment Reviews, 2010, 36, 6, 468

    CrossRef

  31. 31
    Simon Eckermann, Jon Karnon, Andrew R. Willan, The Value of Value of Information, PharmacoEconomics, 2010, 28, 9, 699

    CrossRef

  32. 32
    Elías Moreno, Francisco Javier Girón, Francisco José Vázquez-Polo, Miguel A. Negrín, A Bayesian Net Benefit Approach to Cost-effectiveness Analysis in Health Technology Assessment, International Journal of the Economics of Business, 2009, 16, 3, 323

    CrossRef

  33. 33
    Paolo Pertile, An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography, International Journal of Health Care Finance and Economics, 2009, 9, 3, 317

    CrossRef

  34. 34
    Mart P. Janssen, Hendrik Koffijberg, Enhancing Value of Information Analyses, Value in Health, 2009, 12, 6
  35. 35
    Simon Eckermann, Andrew R. Willan, Globally optimal trial design for local decision making, Health Economics, 2009, 18, 2
  36. 36
    Jonathan Karnon, Jill Carlton, Carolyn Czoski-Murray, Kevin Smith, Informing disinvestment through cost-effectiveness modelling, Applied Health Economics and Health Policy, 2009, 7, 1, 1

    CrossRef

  37. 37
    Ties Hoomans, Elisabeth A. L. Fenwick, Steve Palmer, Karl Claxton, Value of Information and Value of Implementation: Application of an Analytic Framework to Inform Resource Allocation Decisions in Metastatic Hormone-Refractory Prostate Cancer, Value in Health, 2009, 12, 2
  38. 38
    Karl Claxton, Exploring Uncertainty in Cost-Effectiveness Analysis, PharmacoEconomics, 2008, 26, 9, 781

    CrossRef

  39. You have free access to this content39
    N. J. Welton, A. E. Ades, D. M. Caldwell, T. J. Peters, Research prioritization based on expected value of partial perfect information: a case-study on interventions to increase uptake of breast cancer screening, Journal of the Royal Statistical Society: Series A (Statistics in Society), 2008, 171, 4
  40. 40
    Simon Eckermann, Andrew R. Willan, Time and Expected Value of Sample Information Wait for No Patient, Value in Health, 2008, 11, 3
  41. 41
    John Hutton, Paul Trueman, Christopher Henshall, Coverage with Evidence Development: An examination of conceptual and policy issues, International Journal of Technology Assessment in Health Care, 2007, 23, 04

    CrossRef

  42. 42
    Expected Value of Information for Research Prioritization and Study Design,
  43. 43
    Ed Wilson, Keith Abrams, From Evidence-Based Economics to Economics-Based Evidence: Using Systematic Review to Inform the Design of Future Research,